Loading...
A086060 logo

GeneBioTech Co. ,LtdKOSDAQ:A086060 Stock Report

Market Cap ₩35.5b
Share Price
₩4.12k
₩13.57k
69.6% undervalued intrinsic discount
1Y-1.8%
7D1.4%
1D
Portfolio Value
View

GeneBioTech Co. ,Ltd

KOSDAQ:A086060 Stock Report

Market Cap: ₩35.5b

GeneBioTech Ltd (A086060) Stock Overview

Engages in the manufacture and sale of feed additives and functional food in South Korea. More details

A086060 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends2/6

A086060 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

GeneBioTech Co. ,Ltd Competitors

Price History & Performance

Summary of share price highs, lows and changes for GeneBioTech Ltd
Historical stock prices
Current Share Price₩4,120.00
52 Week High₩5,990.00
52 Week Low₩3,600.00
Beta0.43
1 Month Change-14.96%
3 Month Change-20.31%
1 Year Change-1.79%
3 Year Change-8.34%
5 Year Change-34.60%
Change since IPO-51.59%

Recent News & Updates

Analysis Article Nov 14

Investors Continue Waiting On Sidelines For GeneBioTech Co. ,Ltd (KOSDAQ:086060)

When close to half the companies in Korea have price-to-earnings ratios (or "P/E's") above 15x, you may consider...
Analysis Article Aug 11

Here's Why GeneBioTech Ltd (KOSDAQ:086060) Has Caught The Eye Of Investors

KOSDAQ:A086060 1 Year Share Price vs Fair Value Explore GeneBioTech Ltd's Fair Values from the Community and select...

Recent updates

Analysis Article Nov 14

Investors Continue Waiting On Sidelines For GeneBioTech Co. ,Ltd (KOSDAQ:086060)

When close to half the companies in Korea have price-to-earnings ratios (or "P/E's") above 15x, you may consider...
Analysis Article Aug 11

Here's Why GeneBioTech Ltd (KOSDAQ:086060) Has Caught The Eye Of Investors

KOSDAQ:A086060 1 Year Share Price vs Fair Value Explore GeneBioTech Ltd's Fair Values from the Community and select...
Analysis Article May 15

Is GeneBioTech Ltd (KOSDAQ:086060) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article Nov 21

GeneBioTech Ltd's (KOSDAQ:086060) Soft Earnings Are Actually Better Than They Appear

Shareholders appeared unconcerned with GeneBioTech Co. ,Ltd's ( KOSDAQ:086060 ) lackluster earnings report last week...
Analysis Article Aug 12

Market Cool On GeneBioTech Co. ,Ltd's (KOSDAQ:086060) Earnings

It's not a stretch to say that GeneBioTech Co. ,Ltd's ( KOSDAQ:086060 ) price-to-earnings (or "P/E") ratio of 12.9x...
Analysis Article Mar 22

We Like The Quality Of GeneBioTech Ltd's (KOSDAQ:086060) Earnings

GeneBioTech Co. ,Ltd's ( KOSDAQ:086060 ) solid earnings announcement recently didn't do much to the stock price. We did...
Analysis Article Apr 15

Read This Before Buying GeneBioTech Co. ,Ltd (KOSDAQ:086060) For Its Dividend

Today we'll take a closer look at GeneBioTech Co. ,Ltd ( KOSDAQ:086060 ) from a dividend investor's perspective. Owning...
Analysis Article Mar 18

Should GeneBioTech Ltd (KOSDAQ:086060) Be Disappointed With Their 90% Profit?

We believe investing is smart because history shows that stock markets go higher in the long term. But if when you...
Analysis Article Feb 17

Here's Why Genebiotech (KOSDAQ:086060) Has A Meaningful Debt Burden

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article Jan 10

How Does Genebiotech Co., Ltd. (KOSDAQ:086060) Fare As A Dividend Stock?

Could Genebiotech Co., Ltd. ( KOSDAQ:086060 ) be an attractive dividend share to own for the long haul? Investors are...
Analysis Article Nov 19

Is Genebiotech (KOSDAQ:086060) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Shareholder Returns

A086060KR BiotechsKR Market
7D1.4%0.3%4.6%
1Y-1.8%33.0%186.6%

Return vs Industry: A086060 underperformed the KR Biotechs industry which returned 33.1% over the past year.

Return vs Market: A086060 underperformed the KR Market which returned 186.6% over the past year.

Price Volatility

Is A086060's price volatile compared to industry and market?
A086060 volatility
A086060 Average Weekly Movement5.1%
Biotechs Industry Average Movement11.5%
Market Average Movement9.4%
10% most volatile stocks in KR Market16.6%
10% least volatile stocks in KR Market4.9%

Stable Share Price: A086060 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A086060's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200041Chan-Ho Leewww.genebiotech.co.kr

GeneBioTech Co. ,Ltd, together with its subsidiaries, engages in the manufacture and sale of feed additives and functional food in South Korea. It also manufactures and sells animal drugs. The company was founded in 2000 and is headquartered in Gongju-si, South Korea.

GeneBioTech Co. ,Ltd Fundamentals Summary

How do GeneBioTech Ltd's earnings and revenue compare to its market cap?
A086060 fundamental statistics
Market cap₩35.48b
Earnings (TTM)₩3.79b
Revenue (TTM)₩90.79b
9.4x
P/E Ratio
0.4x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A086060 income statement (TTM)
Revenue₩90.79b
Cost of Revenue₩76.53b
Gross Profit₩14.26b
Other Expenses₩10.47b
Earnings₩3.79b

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)440.02
Gross Margin15.70%
Net Profit Margin4.17%
Debt/Equity Ratio26.9%

How did A086060 perform over the long term?

See historical performance and comparison

Dividends

1.2%
Current Dividend Yield
n/a
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/24 10:12
End of Day Share Price 2026/05/22 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GeneBioTech Co. ,Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.